Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises

[1]  Jade Boyd,et al.  Essential work, precarious labour: The need for safer and equitable harm reduction work in the era of COVID-19 , 2020, International Journal of Drug Policy.

[2]  D. Ehrenstein.  How Speaking Creates Droplets That May Spread COVID-19 , 2020 .

[3]  S. Springer,et al.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. , 2020, Journal of substance abuse treatment.

[4]  S. Lyss,et al.  Responding to Outbreaks of Human Immunodeficiency Virus Among Persons Who Inject Drugs-United States, 2016-2019: Perspectives on Recent Experience and Lessons Learned. , 2020, The Journal of infectious diseases.

[5]  M. Tyndall,et al.  Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply. , 2020, Journal of studies on alcohol and drugs.

[6]  B. Lambdin,et al.  Overdose Education and Naloxone Distribution Within Syringe Service Programs — United States, 2019 , 2020, MMWR. Morbidity and mortality weekly report.

[7]  N. Wilson,et al.  Airborne transmission of covid-19 , 2020, BMJ.

[8]  C. Davis,et al.  Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 , 2020, International Journal of Drug Policy.

[9]  D. Ompad,et al.  “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City , 2020, Harm Reduction Journal.

[10]  H. Reed,et al.  The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England , 2020, International Journal of Drug Policy.

[11]  Peter J. Rock,et al.  Signal of increased opioid overdose during COVID-19 from emergency medical services data , 2020, Drug and Alcohol Dependence.

[12]  S. Friedman,et al.  Challenges posed by COVID‐19 to people who inject drugs and lessons from other outbreaks , 2020, Journal of the International AIDS Society.

[13]  L. Metsch,et al.  Syringe services program (SSP) operational changes during the COVID-19 global outbreak , 2020, International Journal of Drug Policy.

[14]  Paul Turnham,et al.  Consideration of the Aerosol Transmission for COVID‐19 and Public Health , 2020, Risk analysis : an official publication of the Society for Risk Analysis.

[15]  D. D. Des Jarlais,et al.  The Impact of COVID-19 on Syringe Services Programs in the United States , 2020, AIDS and Behavior.

[16]  K. Ethier,et al.  Timing of Community Mitigation and Changes in Reported COVID-19 and Community Mobility ― Four U.S. Metropolitan Areas, February 26–April 1, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[17]  P. Adab,et al.  Covid-19: risk factors for severe disease and death , 2020, BMJ.

[18]  D. D. Des Jarlais,et al.  Expansion of Syringe Service Programs in the United States, 2015-2018. , 2020, American journal of public health.

[19]  O. Weiland,et al.  Significant decrease in injection risk behaviours among participants in a needle exchange programme , 2020, Infectious diseases.

[20]  J. Duchin,et al.  Engaging an Unstably Housed Population with Low-Barrier Buprenorphine Treatment at a Syringe Services Program: Lessons Learned from Seattle, Washington , 2019, Substance abuse.

[21]  Ryan D. Ross,et al.  Buprenorphine Treatment Divide by Race/Ethnicity and Payment. , 2019, JAMA psychiatry.

[22]  Kelsey S. Dickson,et al.  Systematic review of the Exploration, Preparation, Implementation, Sustainment (EPIS) framework , 2019, Implementation Science.

[23]  A. Fleischauer,et al.  Trends in Drug UseAssociated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017 , 2018, Annals of Internal Medicine.

[24]  Jonathan Mermin,et al.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016 , 2018, Hepatology.

[25]  Daniel Shearer,et al.  Naloxone distribution, trauma, and supporting community-based overdose responders. , 2019, The International journal on drug policy.

[26]  Christina B. Hanhardt.  "Dead Addicts Don't Recover": ACT UP's Needle Exchange and the Subjects of Queer Activist History , 2018 .

[27]  D. Fast,et al.  “We Don’t Belong There”: New Geographies of Homelessness, Addiction, and Social Control in Vancouver’s Inner City , 2018, City & Society.

[28]  M. Bachhuber,et al.  Description and Outcomes of A Buprenorphine Maintenance Treatment Program Integrated within Prevention Point Philadelphia, An Urban Syringe Exchange Program , 2018, Substance abuse.

[29]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[30]  S. Mars,et al.  Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions. , 2016, Drug and alcohol dependence.

[31]  C. Cunningham,et al.  Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment , 2015, Substance abuse.

[32]  C. Cunningham,et al.  Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. , 2015, Journal of substance abuse treatment.

[33]  Andrea M López.  The Paradoxes of Poverty: Urban Space and Ideologies of Intervention in the "Compassionate" City of San Francisco , 2014 .

[34]  A. Abdul-Quader,et al.  Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review , 2013, AIDS and Behavior.

[35]  C. Cunningham,et al.  Consumer attitudes about opioid addiction treatment: a focus group study in New York City. , 2013, Journal of opioid management.

[36]  T. S. Jones,et al.  Community-based opioid overdose prevention programs providing naloxone - United States, 2010. , 2012, MMWR. Morbidity and mortality weekly report.

[37]  D. D. Des Jarlais,et al.  Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs , 2011 .

[38]  G. Friedland.  Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis , 2010, Journal of acquired immune deficiency syndromes.

[39]  Alex H. Kral,et al.  Overdose Prevention and Naloxone Prescription for Opioid Users in San Francisco , 2010, Journal of Urban Health.

[40]  R. Bluthenthal,et al.  HIV Risks and Seroprevalence Among Mexican American Injection Drug Users in California , 2009, AIDS and Behavior.

[41]  J. Montaner,et al.  Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study , 2008, BMC public health.

[42]  R. Bluthenthal,et al.  Approval of syringe exchange programs in California: results from a local approach to HIV prevention. , 2008, American journal of public health.

[43]  Terry L. Schell,et al.  Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. , 2007, Addiction.

[44]  K. Sporer,et al.  Prescription naloxone: a novel approach to heroin overdose prevention. , 2007, Annals of emergency medicine.

[45]  David R. Thomas,et al.  A General Inductive Approach for Analyzing Qualitative Evaluation Data , 2006 .

[46]  S. Asch,et al.  Unmet need for recommended preventive health services among clients of California syringe exchange programs: implications for quality improvement. , 2006, Drug and alcohol dependence.

[47]  C. McKnight,et al.  Public funding of US Syringe Exchange Programs , 2004, Journal of Urban Health.

[48]  G. Roe.  Harm reduction as paradigm: Is better than bad good enough? The origins of harm reduction , 2005 .

[49]  R. Bluthenthal,et al.  Injection Risk Behaviors Among Clients of Syringe Exchange Programs With Different Syringe Dispensation Policies , 2004, Journal of acquired immune deficiency syndromes.

[50]  C. Newton,et al.  Microbial Infections, Immunomodulation, and Drugs of Abuse , 2003, Clinical Microbiology Reviews.

[51]  Neil Wieloch.  Collective Mobilization and Identity from the Underground: The Deployment of “Oppositional Capital” in the Harm Reduction Movement , 2002 .

[52]  S. Sherman,et al.  Point Defiance: a case study of the United States' first public needle exchange in Tacoma, Washington. , 2001, The International journal on drug policy.

[53]  B. Edlin,et al.  The effect of syringe exchange use on high-risk injection drug users: a cohort study , 2000, AIDS.

[54]  D. Vlahov,et al.  The role of needle exchange programs in HIV prevention. , 1998, Public health reports.

[55]  R. Bluthenthal,et al.  Syringe exchange as a social movement: a case study of harm reduction in Oakland, California. , 1998, Substance use & misuse.

[56]  Lisa D. Moore,et al.  The Social Context of Needle Exchange and User Self-Organization in San Francisco: Possibilities and Pitfalls , 1995 .